Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Change in Accured Expenses for 8 consecutive years, with $4.1 million as the latest value for Q1 2026.

  • Quarterly Change in Accured Expenses fell 40.63% to $4.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Feb 2026, down 4.42% year-over-year, with the annual reading at $17.3 million for FY2025, 46.5% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was $4.1 million at Nurix Therapeutics, down from $11.0 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $11.0 million in Q4 2025, with the low at -$7.0 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $2.6 million, with a median of $3.6 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses surged 314.68% in 2022, then plummeted 402.88% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $3.3 million in 2022, then fell by 6.71% to $3.1 million in 2023, then skyrocketed by 193.46% to $9.0 million in 2024, then rose by 22.36% to $11.0 million in 2025, then tumbled by 62.7% to $4.1 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $4.1 million, $11.0 million, and $6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.